Clinical Trials Logo

Graft Loss clinical trials

View clinical trials related to Graft Loss.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04733131 Active, not recruiting - Immunosuppression Clinical Trials

Long-term Outcomes After Conversion to Belatacept

Start date: January 1, 2004
Phase:
Study type: Observational

belatacept is a selective T-cell co-stimulation blocker that was approved by Food and Drug Administration (FDA) in 2011 for the prophylaxis of graft rejection in adult kidney transplant recipients. This treatment is indicated as an alternative to Calcineurin Inhibitors (CNIs) for prophylaxis of graft rejection in de novo renal transplant recipients. Long term efficacy and safety outcomes of a kidney transplant population converted to a belatacept regimen after transplant have not been yet reported.

NCT ID: NCT03197103 Active, not recruiting - Graft Loss Clinical Trials

The Impact of N-Acetylcysteine on Volumetric Retention of Autologous Fat Graft for Breast Asymmetry Correction

Start date: July 4, 2017
Phase: Phase 4
Study type: Interventional

The aim of this study is to assess the effect of new tumescent solution for liposuction containing N-Acetylcysteine (Pietruski solution) on the autologous fat graft volumetric retention used for healthy women breast asymmetry correction by means of lipofilling.